Part I: Vaccines for solid tumours.

Active specific immunotherapy holds great potential in the search for new therapeutic approaches for patients with cancer. Much preclinical and clinical evidence has shown that the immune system can be polarised against malignant cells by several vaccination strategies. Although no anticancer vaccine can be recommended outside clinical trials at present, tumour response and immunological findings in animals and humans should prompt researchers to investigate further the potential of this biotherapy. We summarise strategies for cancer vaccines so far implemented in the clinical setting, report the results of more than 200 clinical trials published over the past two decades, and discuss insights into preclinical tumour immunology that might aid the design of the next generation of cancer vaccines.

[1]  J. Bystryn,et al.  Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine. , 1992, Cancer research.

[2]  H. Young,et al.  Immortalized Myeloid Suppressor Cells Trigger Apoptosis in Antigen-Activated T Lymphocytes1 , 2000, The Journal of Immunology.

[3]  R. Kennedy,et al.  Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. , 2003, Cancer research.

[4]  Francesco M Marincola,et al.  Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? , 2002, Journal of the National Cancer Institute.

[5]  Mary Collins,et al.  The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. , 2002, Annual review of immunology.

[6]  G. Adams,et al.  Monoclonal antibody therapy for cancer. , 2003, Annual review of medicine.

[7]  F. Marincola,et al.  Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness , 2001, International journal of cancer.

[8]  S. H. van der Burg,et al.  Antibodies against p53 are associated with poor prognosis of colorectal cancer. , 1995, British Journal of Cancer.

[9]  Hua Yu,et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.

[10]  C. Dunton,et al.  Autologous, hapten-modified vaccine as a treatment for human cancers. , 1998, Vaccine.

[11]  C. Arteaga,et al.  Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. , 2003, Cancer research.

[12]  Thierry Boon,et al.  Tumor‐specific shared antigenic peptides recognized by human T cells , 2002, Immunological reviews.

[13]  A. Krieg,et al.  CpG motifs in bacterial DNA and their immune effects. , 2002, Annual review of immunology.

[14]  J. Trapani,et al.  A fresh look at tumor immunosurveillance and immunotherapy , 2001, Nature Immunology.

[15]  N. Chakraborty,et al.  T‐Cell Clones that react against Autologous Human Tumors , 1990, Immunological reviews.

[16]  P. Srivastava,et al.  Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. , 1998, Immunity.

[17]  I. Weissman,et al.  In vivo natural killer cell activities revealed by natural killer cell-deficient mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. A. Sáez,et al.  The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma , 1997, Cancer.

[19]  D. Morton,et al.  Vaccine therapy for malignant melanoma , 1996, CA: a cancer journal for clinicians.

[20]  F. Errington,et al.  A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines , 2003, Nature Medicine.

[21]  J. Sidney,et al.  Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. , 2002, Cancer research.

[22]  D. Goldenberg,et al.  Generation and monitoring of cell lines producing humanized antibodies. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  I. Penn.  Post-Transplant Malignancy , 2000, Drug safety.

[24]  Natale Cascinelli,et al.  Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma , 1996, Cancer.

[25]  V. Sondak,et al.  Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. , 2003, Seminars in cancer biology.

[26]  D. Munn,et al.  IDO and tolerance to tumors. , 2004, Trends in molecular medicine.

[27]  J. Gratama,et al.  IL-12: a promising adjuvant for cancer vaccination , 2003, Cancer Immunology, Immunotherapy.

[28]  Michel C Nussenzweig,et al.  Tolerogenic dendritic cells. , 2003, Annual review of immunology.

[29]  M. Atkins,et al.  Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy , 2002, Journal of immunotherapy.

[30]  M. Mitchell.  Perspective on allogeneic melanoma lysates in active specific immunotherapy. , 1998, Seminars in oncology.

[31]  Ferry Ossendorp,et al.  CD4 T Cells and Their Role in Antitumor Immune Responses , 1999, The Journal of experimental medicine.

[32]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[33]  J. Becker,et al.  A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth , 2002, Nature Network Boston.

[34]  Xia Zhao,et al.  Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  V. Sondak,et al.  Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Mario Roederer,et al.  Ex vivo identification, isolation and analysis of tumor-cytolytic T cells , 2003, Nature Medicine.

[37]  Angus G. Dalgleish,et al.  Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy , 2002, Cancer Immunology, Immunotherapy.

[38]  F. Marincola,et al.  Phase 1 Study in Patients With Metastatic Melanoma of Immunization With Dendritic Cells Presenting Epitopes Derived From the Melanoma-Associated Antigens MART-1 and gp100 , 2000, Journal of immunotherapy.

[39]  N. Ibrahim,et al.  Clinical development of the STn-KLH vaccine (Theratope). , 2003, Clinical breast cancer.

[40]  K. Hellstrand.  Histamine in cancer immunotherapy: a preclinical background. , 2002, Seminars in oncology.

[41]  K. Foon,et al.  Anti-idiotype vaccine against cancer. , 2000, Immunology letters.

[42]  S. Agarwala,et al.  Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment , 2001, Expert opinion on biological therapy.

[43]  F. Marincola,et al.  Cytokines and Immune Response in the Tumor Microenvironment , 2001, Journal of immunotherapy.

[44]  C. Boone,et al.  Virus augmentation of the antigenicity of tumor cell extracts. , 1979, Advances in cancer research.

[45]  Rong Wang,et al.  The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. , 2001, Trends in immunology.

[46]  E. Gilboa,et al.  Induction of Tumor-Specific Cytotoxic T Lymphocytes in Cancer Patients by Autologous Tumor RNA-Transfected Dendritic Cells , 2002, Annals of surgery.

[47]  T. Whiteside,et al.  Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  R. Steinman,et al.  Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. , 2001, Cancer research.

[49]  C. Figdor,et al.  Dendritic cell immunotherapy: mapping the way , 2004, Nature Medicine.

[50]  Javier Hernández,et al.  Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[51]  E. Engleman,et al.  Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy1 , 2001, The Journal of Immunology.

[52]  J. Kirkwood,et al.  Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  G. Wong,et al.  Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  D. Altieri,et al.  Full-length dominant-negative survivin for cancer immunotherapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  G. Schuler,et al.  Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells , 2002, The Journal of experimental medicine.

[56]  J. Kirkwood,et al.  Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB10401+ Patients With Renal Cell Carcinoma or Melanoma , 2002, The Journal of experimental medicine.

[57]  Tomoyuki N. Tanaka,et al.  Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. , 2003, Cancer research.

[58]  A. Moretta.  Natural killer cells and dendritic cells: rendezvous in abused tissues , 2002, Nature Reviews Immunology.

[59]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.

[60]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[61]  J. Dennis,et al.  Glycoprotein glycosylation and cancer progression. , 1999, Biochimica et biophysica acta.

[62]  E. Sercarz,et al.  Genetic vaccination: The advantages of going naked , 1996, Nature Medicine.

[63]  F. Marincola,et al.  Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. , 2001, Cancer research.

[64]  Jay A. Berzofsky,et al.  NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway , 2000, Nature Immunology.

[65]  G. Schuler,et al.  Ex Vivo Isolation and Characterization of Cd4+Cd25+ T Cells with Regulatory Properties from Human Blood , 2001, The Journal of experimental medicine.

[66]  Youjin Lee,et al.  Priming of naive T cells inside tumors leads to eradication of established tumors , 2004, Nature Immunology.

[67]  P. Bruggen,et al.  Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.

[68]  M. Smyth,et al.  Induction of tumor-specific T cell memory by NK cell–mediated tumor rejection , 2002, Nature Immunology.

[69]  P. Kourilsky,et al.  Recombinant viruses as a tool for therapeutic vaccination against human cancers. , 2000, Immunology letters.

[70]  R. Zinkernagel,et al.  Immunotherapy with Dendritic Cells Directed against Tumor Antigens Shared with Normal Host Cells Results in Severe Autoimmune Disease , 2000, The Journal of experimental medicine.

[71]  A. Perelson.  Immune Network Theory , 1989, Immunological reviews.

[72]  A. Diefenbach,et al.  The innate immune response to tumors and its role in the induction of T‐cell immunity , 2002, Immunological reviews.

[73]  Megan Sykes,et al.  Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  F. Marincola,et al.  Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines. , 2003, Biochimica et biophysica acta.

[75]  A. Enk,et al.  Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.

[76]  D. Glass,et al.  Cutting Edge: IL-10-Producing CD4+ T Cells Mediate Tumor Rejection1 , 2002, The Journal of Immunology.

[77]  P. V. van Diest,et al.  Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.